Teplizumab, a new drug, could delay the need for insulin for patients with type 1 diabetes by up to 3 years.
Călin Nicolescu
Health
Foto Pixabay
Always see our news on Google
Teplizumab, a drug already approved in the US, is being tested in the UK to slow the progression of type 1 diabetes by training the immune system to protect pancreatic cells. Hannah Robinson, the first British adult to receive the treatment, hopes it will delay the need for insulin. Experts believe the treatment represents a major change in diabetes management, with the potential to alter the immune process and help high-risk people avoid insulin therapy.
Sources
Un medicament "revoluţionar" ar putea încetini evoluţia diabetului de tip 1. Poate întârzia nevoia de insulină cu 3 ani
Devon mother treated with game-changing diabetes drug
Mother of two becomes the first UK patient to receive ‘groundbreaking’ new diabetes drug
Un medicament „revoluționar”, o nouă speranță pentru diabetul de tip 1. Ce așteptări au medicii
Latest News
22:55
Cristian Bușoi, Secretary of State at the Ministry of Energy, assures that Romanians will not receive double electricity bills for the same consumption next winter
22:48
Police conducted searches in a case involving card fraud after foreign tourists were allegedly deceived in the Old Town.
22:22
Radu Miruță announces measures for Romanian grain exports and denies that Ukrainian trains are being prioritized at the Port of Constanța
22:14
Marco Rubio urges Europe to “wake up from sleep” and strengthen its defense
21:54
Bulgaria invites Romania and Turkey for consultations after drone attacks on commercial vessels in the Black Sea
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
